Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates.

ABSTRACT: Matuzumab and nimotuzumab are anti-EGFR monoclonal antibodies that bind to different epitopes of domain III of EGFR. We developed ⁸⁹Zr-matuzumab as a PET probe for diagnosis/monitoring of response to treatment of a noncompeting anti-EGFR nimotuzumab antibody drug conjugate (ADC) using mouse colorectal cancer (CRC) xenografts. We developed ⁸⁹Zr-matuzumab and performed quality control in EGFR-positive DLD-1 cells. The K_D of matuzumab, DFO-matuzumab and ⁸⁹Zr-matuzumab in DLD-1 cells was 5.9, 6.2 and 3 nM, respectively. A competitive radioligand binding assay showed that ⁸⁹Zr-matuzumab and nimotuzumab bound to noncompeting epitopes of EGFR. MicroPET/CT imaging and biodistribution of ⁸⁹Zr-matuzumab in mice bearing EGFR-positive x

SUBMITTER: Tikum AF 

PROVIDER: S-EPMC9505583 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature